Time course and pattern of first relapse in stage I-II primary cutaneous melanoma: A multivariate analysis of disease-free survival in 3 174 patients followed-up at the Turin Melanoma Centre from 1975 to 2004

Giornale Italiano di Dermatologia e Venereologia

Volumn 140, Issue 3, 2005, Pages 191-200

  Bernengo, M G ^a   Quaglino, P ^a   Cappello, N ^a   Fierro, M T ^a   Doveil, G C ^a   Macripo G ^b   Osella Abate, S ^a   Peroni, A ^a   Lisa, F ^a   Savoia, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Disease free survival; Melanoma follow up; Melanoma recurrence; Multivariate analysis; Prognostic factors

Indexed keywords

ADULT; BODY REGIONS; CANCER CENTER; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; FOOT ULCER; HEALTH HAZARD; HUMAN; INCIDENCE; LEG; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; REVIEW; SKIN METASTASIS; UNIVARIATE ANALYSIS; VISCERAL METASTASIS;

EID: 33646828775     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localised melanoma: a multivariate approach. World J Surg 1992;16:191-5.
2. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998;67:228-33.
3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
4. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5 093 patients. Cancer 1995;75:2484-91.
5. Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004;86:172-8.
6. Eigentler TK, Buettner PG, Leiter U, Garbe C. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry. J Clin Oncol 2004;22:4376-83.
7. Slingluff CL Jr, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer 1992;70:1917-27.
8. Fusi S, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91:94-8.
9. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70.
10. Garbe C, Paul A, Kohler-Spath H, Ellwanger U, Stroebel W, Schwarz M et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol 2003;21:520-9.
11. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL et al. Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 1999;86:2252-8.
12. Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 1994;80:188-97.
13. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999;38:549-57.
14. Bernengo MG, Doveil GC, Lisa F, Pippione M, Aloi FG, Stuardi C et al. Cutaneous melanoma at the Turin Melanoma Center. I. Survival and correlation with clinical and histologic prognostic factors in 502 patients in stage I (1975-1985). G Ital Dermatol Venereol 1986;121:311-26.
15. Bernengo MG, Doveil GC, Lisa F, Stuardi C, Zina G. Cutaneous melanoma at the Turin Melanoma Center. II. Risk of metastasis and free interval in relation to the clinical and histological prognostic factors in 502 patients in stage I (1975-1985). G Ital Dermatol Venereol 1987;122:143-53.
16. Cochran WG. Some methods for strengthening the common c2 tests. Biometrics 1954;10:417-41.
17. Gamel JW, George SL, Edwards MJ, Seigler HF. The long-term clinical course of patients with cutaneous melanoma. Cancer 2002;95:1286-93.
18. Tahery DP, Moy RL. Lack of predictive factors in late recurrence of stage I melanoma. Int J Dermatol 1992;31:629-31.
19. Schmid-Wendtner MH, Baumert J, Schmidt M, Konz B, Holzel D, Plewig G et al. Late metastases of cutaneous melanoma: an analysis of 31 patients. J Am Acad Dermatol 2000;43:605-9.
20. Levy E, Silverman MK, Vossaert KA, Kopf AW, Bart RS, Golomb FM et al. Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors. Melanoma Res 1991;1:63-7.
21. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997;15:2361-70.
22. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988;166:497-502.
23. Franke W, Neumann NJ, Ruzicka T, Schulte KW. Plantar malignant melanoma. A challenge for early recognition. Melanoma Res 2000;10:571-6.
24. rd, Tallapureddy S, Leong SP, Kashani-Sabet M. Prognostic factors in patients with thick cutaneous melanoma (> 4 mm). Cancer 2002;94:1049-56.
25. Garbe C, Buttner P, Bertz J, Burg G, d'Hoedt B, Drepper H et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995;75:2492-98.
26. Talley LI, Soong S, Harrison RA, McCarthy WH, Urist MM, Balch CM. Clinical outcomes of localized melanoma of the foot: a case-control study. J Clin Epidemiol 1998;51:853-7.
27. Walsh SM, Fisher SG, Sage RA. Survival of patients with primary pedal melanoma. J Foot Ankle Surg 2003;42:193-8.
28. Day CL Jr, Sober AJ, Kopf AW, Lew RA, Mihm MC Jr, Golomb FM et al. A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery 1981;89:599-603.
29. Hsueh EC, Lucci A, Qi K, Morton DL. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer 1999;85:383-8.